losartan and ADPKD studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research Excerpts

Excerpt	Relevance	Reference
"In this study, effective BP control was obtained with losartan and ramipril and LVH was found to be regressed significantly in the hypertensive patients with ADPKD."	5.14	A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. ( Kaynar, K; Kiriş, A; Koşucu, P; Orem, C; Ozkan, G; Ulusoy, S, 2010)
"With treatment of prednisolone, an angiotensin-converting enzyme inhibitor, and an angiotensin II receptor-blocker, his proteinuria markedly decreased and renal function was stabilized."	2.43	Nephrotic syndrome and IgA nephropathy in polycystic kidney disease. ( Gejyo, F; Hiura, T; Kawabe, S; Miyamura, S; Nishi, S; Saeki, T; Ueno, M; Yamazaki, H, 2006)
"Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease."	2.43	Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006)

Research

Studies (4)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Ulusoy, S	1
Ozkan, G	1
Orem, C	1
Kaynar, K	1
Koşucu, P	1
Kiriş, A	1
Hiura, T	1
Yamazaki, H	1
Saeki, T	1
Kawabe, S	1
Ueno, M	1
Nishi, S	1
Miyamura, S	1
Gejyo, F	1
Ruggenenti, P	1
Remuzzi, G	1
Goffin, E	1
Pochet, JM	1
Lejuste, P	1
De Plaen, JF	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]	Phase 4	102 participants (Actual)	Interventional	2012-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

HbA1C Levels

Intervention	percentage (Mean)
Insulin Glargine, Metformin, Exenatide	-2.43
Insulin Glargine, Metformin, Prandial Insulin	0.44

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Number of Participants With Hypoglycemia

Intervention	% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide	7.1
Insulin Glargine, Metformin, Prandial Insulin	7.2

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

Weight Change During Trial

Intervention	Participants (Count of Participants)
Insulin Glargine, Metformin, Exenatide	0
Insulin Glargine, Metformin, Prandial Insulin	0

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

Article	Year
Nephrotic syndrome and IgA nephropathy in polycystic kidney disease. Clinical and experimental nephrology, 2006, Volume: 10, Issue:2 Topics: Aged; Biopsy; Dipyridamole; Glomerulonephritis, IGA; Humans; Kidney; Losartan; Male; Nephrotic Syndr	2006
Time to abandon microalbuminuria? Kidney international, 2006, Volume: 70, Issue:7 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers;	2006

losartan and ADPKD